229 related articles for article (PubMed ID: 22973955)
1. Anti-metastatic treatment in colorectal cancer: targeting signaling pathways.
Lemos C; Sack U; Schmid F; Juneja M; Stein U
Curr Pharm Des; 2013; 19(5):841-63. PubMed ID: 22973955
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
Tol J; Punt CJ
Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
[TBL] [Abstract][Full Text] [Related]
3. Integration of novel agents in the treatment of colorectal cancer.
Iqbal S; Lenz HJ
Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
[TBL] [Abstract][Full Text] [Related]
4. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
László L
Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
[TBL] [Abstract][Full Text] [Related]
5. Co-targeting of EGFR and autophagy signaling is an emerging treatment strategy in metastatic colorectal cancer.
Koustas E; Karamouzis MV; Mihailidou C; Schizas D; Papavassiliou AG
Cancer Lett; 2017 Jun; 396():94-102. PubMed ID: 28323034
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor: pathway, therapies, and pipeline.
Goffin JR; Zbuk K
Clin Ther; 2013 Sep; 35(9):1282-303. PubMed ID: 24054705
[TBL] [Abstract][Full Text] [Related]
7. Signal transduction pathways of the epidermal growth factor receptor in colorectal cancer and their inhibition by small molecules.
Efferth T
Curr Med Chem; 2012; 19(33):5735-44. PubMed ID: 23033949
[TBL] [Abstract][Full Text] [Related]
8. Biomarker-driven EGFR therapy improves outcomes in patients with metastatic colorectal cancer.
Hendifar A; Tan CR; Annamalai A; Tuli R
Expert Rev Anticancer Ther; 2014 Sep; 14(9):1051-61. PubMed ID: 24898788
[TBL] [Abstract][Full Text] [Related]
9. Emerging tyrosine kinase inhibitors for the treatment of metastatic colorectal cancer.
Matos I; Elez E; Capdevila J; Tabernero J
Expert Opin Emerg Drugs; 2016 Sep; 21(3):267-82. PubMed ID: 27578253
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer.
Sforza V; Martinelli E; Ciardiello F; Gambardella V; Napolitano S; Martini G; Della Corte C; Cardone C; Ferrara ML; Reginelli A; Liguori G; Belli G; Troiani T
World J Gastroenterol; 2016 Jul; 22(28):6345-61. PubMed ID: 27605871
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.
Jean GW; Shah SR
Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402
[TBL] [Abstract][Full Text] [Related]
12. Cellular signaling pathways implicated in metastasis of colorectal cancer and the associated targeted agents.
Liu X; Ji Q; Fan Z; Li Q
Future Oncol; 2015; 11(21):2911-22. PubMed ID: 26414153
[TBL] [Abstract][Full Text] [Related]
13. Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?
Derangère V; Fumet JD; Boidot R; Bengrine L; Limagne E; Chevriaux A; Vincent J; Ladoire S; Apetoh L; Rébé C; Ghiringhelli F
Oncotarget; 2016 Feb; 7(8):9309-21. PubMed ID: 26824184
[TBL] [Abstract][Full Text] [Related]
14. Spotlight on panitumumab in metastatic colorectal cancer.
Keating GM
BioDrugs; 2010 Aug; 24(4):275-8. PubMed ID: 20623992
[TBL] [Abstract][Full Text] [Related]
15. Targeting metastatic colorectal cancer in 2008: a long way from 5-FU.
Pohl A; Zhang W; Ning Y; Manegold PC; Lurje G; Lenz HJ
Oncology (Williston Park); 2008 Apr; 22(4):456-62; discussion 462-3, 467-8, 474 passim. PubMed ID: 18472617
[TBL] [Abstract][Full Text] [Related]
16. Current and Future Approaches to Target the Epidermal Growth Factor Receptor and Its Downstream Signaling in Metastatic Colorectal Cancer.
Lee MS; Kopetz S
Clin Colorectal Cancer; 2015 Dec; 14(4):203-18. PubMed ID: 26077270
[TBL] [Abstract][Full Text] [Related]
17. Clinical use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer.
Patel DK
Pharmacotherapy; 2008 Nov; 28(11 Pt 2):31S-41S. PubMed ID: 18980550
[TBL] [Abstract][Full Text] [Related]
18. Improving disease control in advanced colorectal cancer: Panitumumab and cetuximab.
Rodríguez J; Viúdez A; Ponz-Sarvisé M; Gil-Aldea I; Chopitea A; García-Foncillas J; Gil-Bazo I
Crit Rev Oncol Hematol; 2010 Jun; 74(3):193-202. PubMed ID: 19700342
[TBL] [Abstract][Full Text] [Related]
19. An overview of experimental and investigational multikinase inhibitors for the treatment of metastatic colorectal cancer.
Lee YC; Michael M; Zalcberg JR
Expert Opin Investig Drugs; 2015; 24(10):1307-20. PubMed ID: 26212373
[TBL] [Abstract][Full Text] [Related]
20. Panitumumab in metastatic colorectal cancer.
Hocking CM; Townsend AR; Price TJ
Expert Rev Anticancer Ther; 2013 Jul; 13(7):781-93. PubMed ID: 23802848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]